-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 3, EVOQ Therapeutics Inc has agreed to license its NanoDisc technology for rheumatoid arthritis (RA) and lupus to Gilead
Sciences, Inc.
, making it possible for EVOQ to obtain up to 6.
585
Billions of dollars in earnings
.
The two companies will collaborate to advance preclinical development, with Gilead responsible for clinical development and commercialization
.
585 Billions of dollars in earnings
.
Gilead will be responsible for clinical development and commercialization
.
"Despite significant progress over the past two decades, there is still a significant unmet need
for people living with inflammatory and autoimmune diseases.
" Executive Vice President, Gilead Research
Dr.
Flavius Martin said, "We are delighted to partner with EVOQ [to address] the needs
of people living with these conditions.
”
Flavius Martin said
EVOQ's technology is designed to enable lymphatic-targeted delivery of disease-specific antigens that have been optimized to deliver antigens to restore immune tolerance
.
The technology has the potential to change the paradigm in the treatment of autoimmune diseases
.
according to
EVOQ, which works mainly by activating dendritic cells, which are abundant in
the human lymphatic system.
Dendritic cells trigger different types of effector T
cells, to coordinate immune responses
against immune tolerance or immune activation.
Depending on the terms of the agreement, EVOQ may receive a total of up to 6.
585
$100 million in advance payments, option exercises and milestone payments for all items, and tiered royalties
on product sales.
Gilead will have the option to exclusively license EVOQ's NanoDisc technology in pursuit of RA
and product candidates for lupus indications
.
Original link: _mstmutation="1" _msthash="220729" _msttexthash="6888128">
